Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics (2019)
Sequence: R8 (octa-arginine)
| Experiment Id | EXP000667 |
|---|---|
| Paper | Cell mimetic liposomal nanocarriers for tailored delivery of vascular therapeutics |
| Peptide | R8+DAG |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 10 mol% (lipid) |
| Rna Concentration | 200 nM |
| Mixing Ratio | 20:1 (lipid:siRNA, w/w) |
| Formulation Format | PEGylated liposome |
| Formulation Components | DOPC/cholesterol/PEG-PE/R8-stearate ± DAG ± PS |
| Size Nm | 60.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | primary human VSMCs; primary human VECs |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown |
| Output Value | ~40–60% GAPDH mRNA reduction |
| Output Units | |
| Output Notes | R8-LDS mediated efficient GAPDH knockdown; DAG/PS increased uptake but did not enhance silencing. |
| Toxicity Notes | Minimal toxicity; DAG reduced R8-mediated toxicity in VSMCs. |
| Curation Notes |